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MicroRNAs (miRNAs) control gene expression by
promoting degradation or repressing translation of
target mRNAs. The components of the miRNA
pathway are subject to diverse modifications that
can modulate the abundance and function of
miRNAs. Iron is essential for fundamental metabolic
processes, and its homeostasis is tightly regulated.
Here we identified iron chelators as a class of acti-
vator of the miRNA pathway that could promote the
processing ofmiRNA precursors.We show that cyto-
solic iron could regulate the activity of the miRNA
pathway through poly(C)-binding protein 2 (PCBP2).
PCBP2 is associated with Dicer and promotes the
processing of miRNA precursors. Cytosolic iron
could modulate the association between PCBP2
and Dicer, as well as the multimerization of PCBP2
and its ability to bind to miRNA precursors, which
can alter the processing of miRNA precursors. Our
findings reveal a role of iron homeostasis in the regu-
lation of miRNA biogenesis.
INTRODUCTION
MicroRNAs (miRNAs) constitute one of the most abundant
classes of gene regulatory molecules in eukaryotic cells. Serving
as guides in RNA-induced silencing complexes, miRNAs direct
Argonaute proteins to specific target mRNAs to repress gene
expression posttranscriptionally (Heo and Kim, 2009). miRNAs
have been shown to shape diverse cellular pathways, from chro-
mosome architecture, development, and growth control to apo-
ptosis and stem cell maintenance (Czech et al., 2008; Ghildiyal
and Zamore, 2009; Kawamura et al., 2008; Kim et al., 2009;
Okamura et al., 2008; Okamura and Lai, 2008; Plasterk, 2006;
Taft et al., 2009). Moreover, the miRNA pathway has been adop-
ted by researchers for RNA interference (RNAi), which has broadCutility in gene-function analysis, drug-target discovery and vali-
dation, and therapeutic development (Dykxhoorn and Lieber-
man, 2006). The endogenous mature miRNA is the product of
multiple processing steps, which are tightly regulated to modu-
late miRNA functions (Heo and Kim, 2009). Chemical biology,
in particular the use of diverse chemicals to interrogate molec-
ular processes, provides a means of rapidly and effectively dis-
secting biological mechanisms and gene networks in ways not
feasible with mutation-based genetic approaches (Hergenr-
other, 2006; Lipinski and Hopkins, 2004; Schreiber, 2005). To
dissect the regulatory mechanisms of modulating the activity
of the miRNA pathway, we previously developed a cell-based
assay to monitor the activity of the miRNA pathway using a
chemical biology approach (Shan et al., 2008).
Iron is the fundamental metal for life processes in an oxygen-
rich atmosphere (Hentze et al., 2004; Lippard and Berg, 1994). It
is a cofactor for the oxygen transporter hemoglobin and partici-
pates in numerous other enzymatic reactions. Iron is involved
in many cellular processes, including respiration and many
key metabolic reactions (Rouault, 2006; Theil and Goss, 2009).
Both iron overload and iron deficiency can lead to cytotoxicity
and cell growth arrest/apoptosis, respectively (Hentze et al.,
2010).
Iron storage and transportation in most mammals are partially
controlled by iron regulatory proteins (IRPs) in a posttranslational
fashion (Rouault, 2006). The IRP system is the most extensively
studied mode of coordinated regulation in iron homeostasis
(Hentze et al., 2004). Trans-acting IRPs, through their metal avail-
ability sensors, interact with ferritin and transferrin receptor (TfR)
iron-responsive elements (IREs), which are conserved hairpin
structures found in messenger RNA (mRNA)-untranslated re-
gions (UTRs), to control either mRNA stability or initiation of
translation. Ferritins are the main iron storage proteins found in
animals. The capacity to store iron in ferritin is essential for life
in mammals, but the mechanism by which cytosolic iron is deliv-
ered to ferritin remained a mystery until recently, when poly(rC)-
binding protein 1 (PCBP1) was found to bind to ferritin in vivo and
facilitate the loading of iron into ferritin (Shi et al., 2008). Deple-
tion of PCBP1 in human cells inhibits ferritin iron loading andell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc. 895
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a cytosolic iron chaperone in the delivery of iron to ferritin. It
was also noted that PCBP2, a paralog of PCBP1, could also
potentially contribute to ferritin iron loading (Shi et al., 2008).
Here we describe the identification, via chemical screen, of
iron chelators as a class of enhancer of the miRNA/RNAi
pathway that could promote the processing of both short hairpin
RNAs (shRNAs) and miRNA precursors. We show that cytosolic
iron regulates the activity of themiRNA pathway through poly(C)-
binding protein 2 (PCBP2). PCBP2 is associated with Dicer and
promotes the processing of miRNA precursors. Cytosolic iron
could modulate the association between PCBP2 and Dicer, as
well as the multimerization of PCBP2 and its ability to bind to
miRNA precursors, which can alter the processing of miRNA
precursors. Our findings reveal a role of iron homeostasis in
the regulation of miRNA biogenesis, and indicate that altered
miRNA expression might contribute directly to the molecular
pathogenesis of human diseases associated with disrupted
iron homeostasis. Our results also suggest potential use of iron
chelators to modulate the activity of the miRNA pathway.
RESULTS
Identification of Metal Chelators as a Class
of shRNA-Mediated RNAi Enhancer
We previously developed a cell-based assay (RNAi-293-EGFP)
to monitor the activity of the RNAi pathway using EGFP as
a reporter (Shan et al., 2008). In this system, a HEK293-derived
stable cell line expressing a GFP reporter gene (293-EGFP)
was infected with a lentivirus expressing a shRNA that is pro-
cessed into small interfering RNAs (siRNAs) specifically targeting
GFP. Here we further optimized this system by introducing RFP
into this reporter cell line as an internal control, so the GFP/RFP
ratio would better reflect the activity of the miRNA/RNAi
pathway. Using this modified system, we screened additional
libraries and identified several structurally diverse small mole-
cules with metal chelation activity that could enhance the activity
of the RNAi pathway (Figure 1A and Figure S1A available online).
The enhancement by metal chelators was further confirmed with
additional shRNAs targeting both endogenous and additional
reporter genes, indicating that the effect of thesemetal chelators
on shRNA-mediated gene knockdown is universal (Figures 1B
and S1B).
Through our initial screenwe identified deferoxaminemesylate
as a potent enhancer of the shRNA-mediated RNAi-enhancing
activity. Deferoxamine mesylate is a well-known ligand for iron
that exhibits iron chelation in vivo (Richardson and Ponka,
1998). We performed further tests and found that 1-(dipyridinyl-
methylene) thiosemicarbazide, another known iron chelator, also
exhibits the same effect (Figures 1A and S1A). A broader screen
of a variety of ligands indicated that neither diimines nor oxygen
ligands, such as crown ethers, diacids, and amino alcohols, had
any effect on shRNA-mediated RNAi, whereas iron chelators,
such as pyridine-based ligands and some salen ligands, display
significant RNAi-enhancing activity (Figure 2) (Whitnall et al.,
2006). In addition, the common metal chelator 2,20-dipyridyl,
but not its inactive isomer 4,40-bipyridyl, could enhance
shRNA-mediated RNAi (Figures 1C and S2A) (Rosner et al.,
2002). These results together strongly suggest that iron chelating896 Cell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc.activity is required for the RNAi-enhancing activity we observed.
Among the small molecules we tested, we chose dipyridine for
our follow-up studies, due to its small size as well as the avail-
ability of the inactive form of 4,40-bipyridyl for control experi-
ments. Similar RNAi-enhancing activity by iron chelator could
also be observed in a hepatoma cell line (HepG2), which plays
a critical role in regulating iron homeostasis (Figure S1C).
Cytosolic Iron Modulates the Activity of the RNAi
Pathway
Since the metal chelators we tested above could potentially
chelatemultiplemetals, we determinedwhichmetals specifically
modulate the activity of the RNAi pathway by performing a metal
substitution assay using our RNAi reporter system. In this assay,
our reporter cell line was grown in serum-free medium that was
supplemented with different metals, including manganese, zinc,
copper, nickel, cobalt, and iron. The RNAi activity for each was
determined by measuring the GFP/RFP ratio. Among the metals
we tested at comparable toxicity levels, only iron could signifi-
cantly increase the GFP/RFP ratio and inhibit RNAi activity, sug-
gesting that intracellular iron can modulate the activity of the
RNAi pathway (Figure 1D).
Cellular iron is well known to be tightly regulated and compart-
mentalized by nature to maximize controlled reactions with
oxygen in cells (Hentze et al., 2004; Rouault, 2009). Once trans-
ported into the cells by transferrin or through other pathways,
iron is distributed in three main compartments for different func-
tions. In mitochondria, iron is mainly for biosynthesis of heme
and Fe-S clusters. Surplus iron goes to ferritin for storage in cyto-
plasm. Heme serves as a prosthetic group for many cellular
proteins with diverse biological functions (Rouault and Tong,
2008). Because iron chelators can also block heme biogenesis,
we wanted to explore whether heme is involved in the RNAi
pathway. Thus, our reporter cell line was cultured in serum-free
medium supplemented with succinylacetone (SA) to deplete
heme as described previously (Yin et al., 2007). Heme depletion
was confirmed by heme quantification (Figure S2B). Further-
more, we also included a panel with both SA treatment and the
addition of different concentrations of heme. We saw no alter-
ation of RNAi activity with SA treatment in the presence or
absence of heme, which suggests that heme is not involved in
modulating the activity of the RNAi pathway (Figure S2C). In
addition, we performed knockdown experiments using siRNAs
against the heavy chain subunit of ferritin and transferrin receptor
1 (TFR1) and found that the reduction of ferritin or TFR1, which
would alter the level of cytosolic iron, could modulate shRNA-
mediated RNAi (Figures S2D–S2F). Finally, we altered the cyto-
solic iron level by manipulating the expression level of ferropor-
tin, an iron exporter, and observed similar effects on the activity
of the RNAi pathway (Figure S2G). These results together
suggest that the cytosolic iron level regulates the activity of the
RNAi pathway.
Iron Chelator Promotes the Processing of shRNAs and
miRNA Precursors
Since there are two approaches to induce the specific suppres-
sion of gene expression in cells, shRNAs and siRNA duplexes,
we also tested siRNA duplexes and found that iron chelator
has no effect on siRNA duplex-induced RNAi, while the shRNAs
Figure 1. Identification of Iron Chelators as
a Class of shRNA-Mediated RNAi Enhancer
via Chemical Screen
(A) Iron chelators enhance shRNA-EGFP-
mediated gene silencing. DMSO was used as
a negative control, whereas enoxacin, a previously
identified RNAi enhancer, was used as a positive
control. Values are mean ± SD for triplicate
samples. *p < 0.001 when metal chelators were
compared with control or enoxacin, and enoxacin
was compared with control. The left panel shows
the relative GFP/RFP ratios, while the right panel
shows the GFP mRNA level determined by quan-
titative RT-PCR. Values are mean ± SD for tripli-
cate samples.
(B) The metal chelator 2,20-dipyridyl enhances
shGAPDH-mediated gene silencing. The GAPDH
protein levels were detected by western blots with
anti-GAPDH antibody, with Spectrin used as a
loading control. Metal chelator has no effect on
GAPDH expression in shVC control cells. Values
are mean ± SD for triplicate samples. *p < 0.001
when shGAPDH treated with 2,20-dipyridyl was
compared with shGAPDH control, and shGAPDH
control was compared with shVC.
(C) The iron chelator 2,20-dipyridyl, but not its
inactive isomer 4,40-bipyridyl, could enhance
shRNA-mediated RNAi. Three reporter cell lines,
shGFP, shLuciferase, and shGAPDH, were treated
with 2,20-dipyridyl and its isoform 4,40-bipyridyl for
48 hr before analyses. Values are mean ± SD for
triplicate samples. *p < 0.001 when 2,20-dipyridyl
was compared with control (DMSO) and 4,40-
bipyridyl.
(D) Iron specifically regulates the activity of the
RNAi pathway. A metal substitution assay was
performed with RNAi-293-EGFP/RFP reporter
cells. The reporter cells were seeded in FBS-free
DMEM supplemented with different metals at
comparable toxicity levels for 24 hr before
measuring relative fluorescence intensity. Values
are mean ± SD for triplicate samples. *p < 0.001.
See also Figures S1 and S2.
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ure 3A). We further examined the expression of mature small
RNAs in cells expressing different shRNAs (Figures 3B and
S3A). Although different promoters were used in these con-
structs, we observed consistent increases of processed siRNAs
and corresponding decreases of shRNAs in cells treated with
iron chelator (Figures 3B and S3A). Furthermore, we examined
the levels of the mature form of miR-125a, pri-miR-125a, and
pre-miR-125a in cells stably overexpressing the primary tran-
script of miR-125a (Pri-miR-125a) that we described previously
by quantitative RT-PCR (Figure 3C) (Duan et al., 2007). The addi-
tion of iron chelator led to increases in the mature form of
miR-125a and corresponding decreases in the levels of both
pre-miRNA and pri-miRNA (Figure 3C). This suggests that iron
chelator can promote the processing of miR-125a. Since the
shGFP used in our initial reporter system mimics miRNA precur-
sors and is therefore processed by Dicer, these data suggestCthat iron chelator may function at the level of Dicer-mediated
precursor processing. To test this possibility, we usedmicroRNA
TaqMan assays to profile miRNA expression in the presence or
absence of iron chelator. The majority of endogenous miRNAs
(313/369) were not affected (data not shown). Among the
miRNAs consistently altered by iron chelator, all showed in-
creased expression of the mature form (Figures 3C, 3D, and
S3B–S3E). Reminiscent of miR-125a, we also found decreased
levels of the pri- and pre- forms of some of the miRNAs whose
mature forms increased in the presence of metal chelator (Fig-
ure 3C and S4A). Interestingly, we noted that the precursor forms
of the elevated endogenous miRNAs are generally abundant in
untreated cells, while the endogenous miRNAs that are not
significantly affected by iron chelator generally have very few
or no detectable precursors in cells (Table S1). Furthermore,
iron chelator treatment could increase the production of mature
small RNAs from the miR-30a-based shRNAs (precursor-likeell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc. 897
Figure 2. The RNAi-Enhancing Activity of Different Classes of Metal Chelators
Chemical structures of small molecules tested are shown. DMSOwas used as a negative control. The relative GFP/RFP ratio for each small molecule is shown on
the bottom. See also Figure S2.
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effect on endogenous miR-30a, which had no detectable
steady-state precursor form in cells (Figure S3). Similar enhance-
ment of miRNA processing by iron chelator could be seen in
HepG2 cells, as well (Figure S1D). These data together show
that iron chelator can promote processing of both shRNA and
miRNA precursors, which depends largely on the amount of
precursor RNA in cells, rather than specific RNA sequences.
The increased miRNA processing could impact the miRNA-
mediated posttranscriptional regulation on the mRNA tar-
gets that were identified previously (Figure S4B and S4C) (Le
et al., 2011; Le et al., 2009; Szulwach et al., 2010; Zhang et al.,
2009).
Although our heme depletion assay suggests that heme is not
involved in modulating the activity of the RNAi pathway (Fig-
ure S2C), a previous in vitro study suggested that heme is
a cofactor of DGCR8, which is associated with Drosha and
involved in pri-miRNA processing (Faller et al., 2007). To address
this apparent discrepancy, we depleted heme in cells stably
overexpressing the primary transcript of miR-125a (Pri-miR-
125a) and examined the processing of miR-125a. Consistent
with the results from our RNAi reporter assay, we saw no signif-
icant change in miR-125a processing (Figure S4D).
PCBP2 Mediates the Modulation of RNAi by Cytosolic
Iron via Interactions with Dicer
Iron regulatory proteins 1 and 2 (IRP1 and IRP2) are mammalian
proteins that register cytosolic iron concentrations and posttran-898 Cell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc.scriptionally regulate expression of iron metabolism genes to
optimize cellular iron availability via interaction with IREs in
mRNA (Rouault, 2006). Most recently, PCBP1 was identified as
a cytosolic iron chaperone (Shi et al., 2008). It was also noted
that PCBP2, a paralog of PCBP1, could potentially contribute
to ferritin iron loading, as well (Shi et al., 2008). Because iron
chelator could promote the processing of shRNAs and miRNA
precursors, we next examined whether any of these proteins is
associated with Dicer, the core component of miRNA precursor
processing complex (Krol et al., 2010). We performed reciprocal
coimmunoprecipitation experiments followed by western blot
analyses using HEK293 cells transfected with FLAG-Dicer and
IRP1, IRP2, PCBP1, or PCBP2 expression vectors (Paroo
et al., 2009). We found that only PCBP2, but not other proteins,
could be coimmunoprecipitated with Dicer. This association is
RNA-independent, since the lysate used for immunoprecipita-
tion was pretreated with RNase (Figure 4A and S5A). Interest-
ingly, the association between PCBP2 and Dicer could be
enhanced significantly by iron chelator (Figure 4A). These obser-
vations were further confirmed by the coimmunoprecipitation
experiment using the antibodies recognizing the endogenous
PCBP2 and Dicer proteins (Figure 4B). Furthermore, the addition
of iron to the immunoprecipitation buffer could partially abolish
the enhanced association between PCBP2 and Dicer by iron
chelator (Figure 4C). We also used the siRNAs against each of
these genes to knockdown their expression in our EGFP reporter
cells and found again that only the knockdown of PCBP2 could
block the RNAi-enhancing activity of iron chelator (Figure 4D and
Figure 3. Iron Chelator Promotes the Processing of shRNAs and miRNA Precursors
(A) Metal chelator enhances only shRNA-mediated but not synthetic siRNA duplex-induced knockdown. Knockdown of each mRNA was graphed as the
percentage of mock-treated samples in the presence or absence of metal chelators (2,20-dipyridyl). Values are mean ± SD for triplicate samples. *p < 0.001.
Control was transfected with control siRNA duplex.
(B) Quantitative RT-PCR was used to measure the levels of processed siRNA and shRNA in RNAi-293-EGFP/RFP reporter cells. 5S was used as an internal
control. Values are mean ± SD for triplicate samples. *p < 0.001.
(C) Quantitative RT-PCR was used to measure the levels of pri-, pre-, and mature forms of miR-125a and miR-203 in mock- and iron chelator-treated HEK293
cells expressing the primary transcript of miR-125a. The relative expression levels as determined byDDCt analyses are shown. Values aremean ± SD for triplicate
samples. *p < 0.001.
(D) Relative quantity of miRNA with consistent changes in expression shown for iron chelator-treated HEK293 cells (transfected HEK293 cells stably expressing
pri-miR-125a were used), calibrated to mock-treated cells (mock-treated relative quantity = 1; the mean relative quantity from three pairs is plotted with error
represented as a 95% confidence interval).
See also Figures S3 and S4 and Table S1.
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themodulation of the RNAi pathway by cytosolic iron via interac-
tion with Dicer in an iron-dependent manner.
PCBP2 (or hnRNP-E2) is a member of a family of four homol-
ogous RNA-binding proteins belonging to the heterogeneous
nuclear ribonucleoprotein K-homology domain superfamily and
is widely expressed and highly conserved among mammals
(Makeyev and Liebhaber, 2002). This group of proteins is
believed to play roles in mRNA stabilization, translational activa-
tion, and translational silencing (Makeyev and Liebhaber, 2002).
Intriguingly, miR-328 was recently shown to compete with other
RNAs for PCBP2 binding (Eiring et al., 2010). To determineCwhether PCBP2 itself is involved in the miRNA/RNAi pathway,
we knocked down the expression of PCBP2 in different
shRNA-mediated RNAi reporter systems we have used. We
found that the reduction of PCBP2 could consistently decrease
the shRNA-mediated knockdown efficiency of these systems
(Figures 5A and S5C). Furthermore, the knockdown of PCBP2
could inhibit the processing of both shRNA and miRNA precur-
sors and block the enhanced miRNA processing mediated by
iron chelator (Figures 5B, 5C, and S5D–S5E). These findings
together suggest that PCBP2 is involved in the miRNA/RNAi
pathway and can regulate the processing of miRNA precursors
or shRNAs.ell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc. 899
Figure 4. PCBP2 Mediates the Modulation of the RNAi Pathway by
Cytosolic Iron via Interaction with Dicer
(A) Iron modulates the association between exogenous PCBP2 and Dicer. The
upper-middle panel shows the western blot to detect the coimmunoprecipi-
tated FLAG-Dicer protein in the immunoprecipitated complex with anti-MYC
antibody under different conditions. The lower-middle panel indicates the
immunoprecipitated MYC-PCBP2. The upper-right panel shows the immu-
noprecipitated FLAG-Dicer, while the lower-right panel shows the western blot
to detect the coimmunoprecipitated MYC-PCBP2 protein in the immunopre-
cipitated complex (IP) with anti-FLAG antibody under different conditions. The
cells were treated with DMSO or 2,20-dipyridyl for 48 hr before immunopre-
cipitation. Ten percent input and 50% IP were loaded.
(B) Iron modulates the association between endogenous PCBP2 and Dicer
proteins. The upper panel shows the western blot to detect the Dicer protein in
the immunoprecipitatedcomplexor inputwithanti-Dicerantibodyunderdifferent
conditions. The lower panel indicates the PCBP2 in the immunoprecipitated
complex or input with anti-PCBP2 antibody under different conditions. The cells
were treated with DMSO or 2,20-dipyridyl for 48 hr before immunoprecipitation.
(C) The addition of iron to the IP buffer decreases the association between
PCBP2 and Dicer. Immunoprecipitation experiments similar to (A) were per-
formed with the addition of iron in the IP buffer.
(D) The RNAi-enhancing activity of iron chelators is PCBP2-dependent. The
siRNAs against IRP1, IRP2, PCBP1, PCBP2, and Dicer were transfected into
the RNAi-293-EGFP/RFP reporter cells. The cells were then treated with
DMSO or 2,20-dipyridyl for 48 hr before RNAi-enhancing activity was deter-
mined. Values are mean ± SD for triplicate samples. *p < 0.001.
See also Figures S4 and S5.
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900 Cell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc.Cytosolic IronModulates PCBP2Multimerization and Its
Association with Pre-miRNAs
Since PCBP2 could bind to RNA and regulate the processing of
miRNA precursors, we next examined whether PCBP2 could
bind to miRNA precursors. Using HEK293 cells stably overex-
pressing pri-miR-125a transfected with MYC-PCBP2 expres-
sion vector, we isolated PCBP2-containing protein-RNA com-
plexes through immunoprecipitation and found that PCBP2 is
indeed associated with miR-125a precursor, but not pri-miR-
125a (Figure 6A). Furthermore, the amount of miR-125a
precursor associated with PCBP2 increased significantly with
iron chelator treatment, despite the fact that a similar amount
of PCBP2 protein was immunoprecipitated (Figure 6A). This
enhanced association could be disrupted by the addition of
iron to the immunoprecipitation buffer. We also saw similar
enhanced associations between PCBP2 and other miRNA
precursors as a result of iron chelator (Figure S6A). To further
delineate the role of iron in the interaction between PCBP2 and
miRNA precursor, we performed a series of in vitro RNA-binding
assays using recombinant PCBP2 and let-7 precursor. We found
that iron could indeed directly disrupt the interaction between
PCBP2 and miRNA precursor, which could be rescued by
2,20-dipyridyl, but not its inactive isomer, 4,40-bipyridyl (Figures
6B and S6B). Furthermore, the removal of loop region from
miRNA precursor could significantly abolish the binding of
PCBP2 to miRNA precursor (Figure S6C). Since PCBP2 was
found to prefer binding to C-rich RNAs, we further examined
the sequences of the loop regions of these pre-miRNAs, and
did not observe the specific C enrichment within these regions
(Makeyev and Liebhaber, 2002).
To determine the functional relevance of the PCBP2-Dicer
interaction, we performed an in vitro miRNA precursor process-
ing assay. The addition of recombinant PCBP2 could sig-
nificantly enhance the processing of let-7 miRNA precursor by
recombinant Dicer (Figures 6C and S6F). However, PCBP1, the
other cytosolic iron chaperone and an ortholog of PCBP2, could
not enhance Dicer-mediated miRNA processing in vitro while
iron has no significant impact on Dicer activity along, either
(Figures S4D and S4E). Similar enhancement could be observed
with other miRNA precursor as well (Figure S6G). These findings
together suggest that PCBP2 can bind to miRNA precursors and
present them to Dicer for more efficient miRNA processing.
Cytosolic iron could modulate this process by disrupting the
interactions between PCBP2 and miRNA precursors, as well
as Dicer.
Finally, previous studies have shown that, as an RNA-binding
protein, the multimerization of PCBP2 is required for its interac-
tion with RNA and gene regulation (Bedard et al., 2004; Du et al.,
2008). Particularly, the second KHdomain of PCBP2 is critical for
its multimerization. To determine whether cytosolic iron could
modulate the multimerization of PCBP2, we performed coimmu-
noprecipitation experiments followed by western blot analyses
using HEK293 cells cotransfected with PCBP2 expression
vectors carrying different tags at the N-terminals, MYC and
HA, respectively. As shown in Figure 6D, the multimerization of
PCBP2 could be enhanced significantly by the addition of iron
chelator, suggesting that iron can indeed modulate the multime-
rization of PCBP2. To further explore the functional relevance of
PCBP2 multimerization in the RNAi pathway, we utilized an
Figure 5. PCBP2 Modulates the Activity of the RNAi/MicroRNA
Pathway
(A) The knockdown of PCBP2 inhibits the shRNA-mediated RNAi. The cells
expressing either shVC or shGAPDH were transfected with siRNA against
PCBP2 or siNC (control siRNA). The GAPDHmRNA levels were determined by
quantitative RT-PCR. Knockdown of PCBP2 has no effect on GAPDH
expression in shVC control cells. Values are mean ± SD for triplicate samples.
*: p < 0.001.
(B) The knockdown of PCBP2 blocks the processing of shRNA. Values are
mean ± SD for triplicate samples. *p < 0.001.
(C) The knockdown of PCBP2 blocks the processing ofmiRNA precursors. The
panel shows the processing of miR-125a. Values are mean ± SD for triplicate
samples. *p < 0.001.
See also Figure S5.
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which was published previously, to examine its association
with Dicer and effect on the activity of the RNAi pathway (BedardCet al., 2004). We did not detect the association between mutant
PCBP2 and Dicer, and found that the mutant PCBP2 could not
enhance the activity of the RNAi pathway (Figures 6E and
S6H). Our results indicate that the mutant PCBP2 lacking multi-
merization activity could not regulate miRNA processing.
DISCUSSION
miRNAs constitute a large family of small regulatory RNAs that
have emerged as key posttranscriptional regulators of gene
expression inmetazoans and plants, revolutionizing our compre-
hension of the posttranscriptional regulation of gene expression
(Krol et al., 2010). miRNAs and their associated proteins are
subject to diverse modifications that can impinge on their abun-
dance and function (Kim et al., 2010). Iron is essential for funda-
mental metabolic processes in cells and organisms. Cellular iron
uptake, distribution, and export must be tightly regulated, as
insufficient iron concentrations impair the function of numerous
iron proteins, whereas excess free iron can oxidize and damage
the protein, nucleic acid, and lipid contents of cells (Hentze et al.,
2010). Here, through a chemical screen, we identified iron chela-
tors as a class of shRNA-mediated RNAi enhancer and uncov-
ered a role for iron homeostasis in directly modulating the activity
of themiRNA/RNAi pathway. Our results suggest potential use of
iron chelators to modulate the activity of the miRNA pathway.
Iron is a critical nutrient required for DNA synthesis, energy
production, and normal cellular growth. Once iron enters the
cells, the majority of iron is routed to the mitochondria, where
substantial amounts are needed for heme biosynthesis and
maturation of the Fe-S cluster, while the portion not needed for
immediate use is stored by ferritin, a ubiquitous and highly
conserved multimeric protein. Tight regulation of iron uptake,
distribution, and export is mediated through transport, storage,
and regulatory proteins (Hentze et al., 2004). The concentration
of cytosolic iron is carefully controlled in normal tissue, because
cytosolic iron is toxic when present in excess. In the presence of
molecular oxygen, iron salts are able to redox cycle between iron
(II) and iron (III) and thereby generate highly reactive free radicals,
such as hydroxyl radicals, which lead to oxidative tissue
damage. Cellular iron levels are predominantly balanced by the
IRE/IRP regulatory system (Rouault, 2006). Ferritins are the
main iron storage proteins found in animals, plants, and bacteria.
The capacity to store iron in ferritin is essential for life in
mammals. Both PCBP1 and PCBP2 have been implicated to
contribute to ferritin iron loading (Shi et al., 2008). Our results
suggest that cytosolic iron, but not heme, could modulate the
activity of the miRNA pathway. Whether the administration of
iron chelator into an intact organism could affect the in vivo
miRNA processing would need to be further tested.
We show that PCBP2, but not PCBP1, mediates this process
by associating with Dicer. This specificity is particularly intriguing
given the high similarity between these two proteins (Makeyev
and Liebhaber, 2002). Indeed, an earlier proteomic analysis of
Argonaute-containing mRNA-protein complexes in human cells
suggested that PCBP2 (hnRNP E2), but not PCBP1, is associ-
ated with Argonaute 1 protein-containing complex with Dicer
activity (Ho¨ck et al., 2007). These data together suggest that
specific domain(s) mediating the association with Dicer activity
might only be present in PCBP2 protein, which would needell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc. 901
Figure 6. Cytosolic Iron Modulates the Multimeri-
zation of PCBP2 and Its Association with miRNA
Precursor
(A) Iron chelator increases the amount of miRNA precursor
associated with PCBP2 in vivo. The bottom panel shows
the western blot to detect the MYC-PCBP2 in the immu-
noprecipitated complex using anti-MYC antibody under
different conditions. The top panel shows the amount of
miR-125a precursor associated with PCBP2 determined
by quantitative RT-PCR. Values are mean ± SD for tripli-
cate samples. *p < 0.001.
(B) Iron blocks the binding of PCBP2 to miRNA precursor
in vitro. RNA filter-binding assay with recombinant PCBP2
protein (100 nM) and 50-32P-labeled let-7 precursor in the
presence or absence of different dosages of iron is shown.
Values are mean ± SD for triplicate samples.
(C) The left panel shows in vitro processing of radioactively
labeled let-7 precursor by either Dicer alone or Dicer with
PCBP2. Both the precursor and processed miRNAs are
indicated. The right panel shows the averages of relative
cleavage activity from three independent experiments.
*p < 0.001, **p < 0.01.
(D) Iron chelator enhances the multimerization of PCBP2.
293FT cells were transfected with MYC-PCBP2 and HA-
PCBP2 expression vectors, which were then treated with
iron chelators for 36 hr before immunoprecipitation (IP).
Shown is the western blot to detect the coimmunopreci-
pitated HA-PCBP2 in the immunoprecipitated complex
with anti-MYC antibody.
(E) PCBP2 multimerization is required to promote miRNA
biogenesis. The cells stably overexpressing shLuciferase
were transfected with Luciferase reporter construct along
with pCDNA vector alone, pCDNA-PCBP2, or pCDNA
Mutant PCBP2. The cells were analyzed at 48 hr after
transfection. Values are mean ± SD for triplicate samples.
*p < 0.001.
See also Figure S6.
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Iron Homeostasis and MicroRNA Pathwayfurther investigation. Furthermore, our in vitro studies suggest
that cytosolic iron could regulate the multimerization of
PCBP2, which is required for its interaction with miRNA precur-
sors. These findings reveal a dynamic regulation mediated by
cytosolic iron, which is itself being tightly regulated. When cyto-
solic iron is low, PCBP2 could multimerize, bind to miRNA
precursors, and present them to Dicer for more efficient miRNA
processing. Excess cytosolic ironwill interfere with the binding of
PCBP2 to miRNA precursors as well as its association with
Dicer, and lead to the reduced production of mature miRNAs.
Disruptions in iron homeostasis from iron deficiency and over-
load account for some of the most common human diseases.
Iron deficiency is the leading cause of anemia in the world, and
it interferes significantly with normal cognitive development in
children. Conversely, the iron overload observed in common
diseases like hemochromatosis and thalassemia results in liver
and heart failure (Muckenthaler et al., 2008). Our findings here
suggest that disruptions in iron homeostasis could alter the pro-
cessing of miRNA precursor and the production of selective
mature miRNAs, whose precursors are present abundantly at
steady state in cells. Thus, the altered expression of cell type-
specific miRNAsmight contribute to the molecular pathogenesis
of human diseases associated with disrupted iron homeostasis.
Iron chelators are being developed to treat different human
diseases, including both cancer and neurodegenerative disor-
ders. Many in vitro and in vivo studies have shown that, com-902 Cell Metabolism 15, 895–904, June 6, 2012 ª2012 Elsevier Inc.pared with normal cells, cancer cells are more sensitive to Fe
deprivation, because of their marked Fe requirements (Richard-
son, 2002). To facilitate rapid replication, neoplastic cells have
significantly higher levels of ribonucleotide reductase and the
transferrin receptor 1. The higher Fe utilization by cancer cells
versus their normal counterparts provides a rationale for the
selective antitumor activity of iron chelators, so depriving
cancer cells of their essential iron is a approach for cancer
treatment (Whitnall and Richardson, 2006). The etiology of
neurodegenerative diseases, such as Parkinson’s disease, Alz-
heimer’s disease, amyotrophic lateral sclerosis, and other neu-
rodegenerative diseases, is not yet well understood. Over the
last two decades, accumulating evidence has pointed to iron-
dependent oxidative stress, elevated levels of iron, and deple-
tion of antioxidants in the brain as major pathogenic factors
(Whitnall and Richardson, 2006). Indeed, iron chelators have
shown efficacy in a variety of cellular and animal models of
central nervous system injury. More recently, RNAi technology
has been under rapid development to treat human diseases,
and several pilot RNAi clinical studies are underway to test
the therapeutic utility of RNAi-based approaches (Vaishnaw
et al., 2010). The identification of iron chelator as an enhancer
of shRNA-mediated RNAi could give a push to this develop-
ment. Our results hold out the hope that combining these two
approaches might have a synergistic effect and make for better
therapeutic interventions.
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Iron Homeostasis and MicroRNA PathwayIn summary, via chemical screen, we identified iron chelators
as a class of activator of the miRNA pathway that could promote
the processing of both shRNAs andmiRNAprecursors.We show
that cytosolic iron regulates the activity of the miRNA pathway
through PCBP2. PCBP2 is associated with Dicer and promotes
the processing of miRNA precursors. Cytosolic iron couldmodu-
late the association between PCBP2 and Dicer, as well as the
multimerization of PCBP2 and its ability to bind tomiRNA precur-
sors. Our findings not only reveal the role of iron homeostasis in
the regulation of miRNA biogenesis, but also suggest potential
use of iron chelators to modulate the activity of the miRNA
pathway.
EXPERIMENTAL PROCEDURES
Cells and Small-Molecule Screen
293FT cells, NIH 3T3 cells, shLuciferase cells, shVector control cells,
shGAPDH cells, shHtt cells, and RNAi-293-EGFP cells coexpressing EGFP
and shEGFP were grown and maintained as described previously (Shan
et al., 2008).
RNAi-293-EGFP cells were infected with Lenti-RFP (Lentigen) and then
subcloned to generate stable RNAi-293-EGFP/RFP reporter cells. Small mole-
cule libraries, including both The Spectrum Collection and The Structural
Diversity Set from the National Cancer Institute (NCI), were used for the chem-
ical screen with RNAi-293-EGFP/RFP cells as described previously (Shan
et al., 2008). In brief, cells were seeded into 96-well plates. Two thousand indi-
vidual drugs from The Spectrum Collection (MicroSource Discovery Systems)
and The Structural Diversity Set (NCI) were added into individual wells at a final
concentration of 10 mM in 48 hr. GFP and RFP fluorescence intensity was
measured in 48 hr on an Analyst HT plate reader (Molecular Devices).
Metal Substitution Assay
RNAi-293-EGFP/RFP cells grown on regular DMEM supplemented with 10%
heat-inactivated FBS were seeded into 96-well plates with FBS-free media
overnight before metals were added. Metals, including iron, copper, zinc,
nickel, maganese, and cobalt, were tested.
DNA Constructs
FLAG-Dicer expression vector was described previously (Paroo et al., 2009).
Full-length PCBP1 and PCBP2 complementary DNAs were cloned into
pcDNA3 vectors containing MYC or HA tag. Full-length PCBP1 and PCBP2
cDNAs were also cloned into pET-28a (+) to produce recombinant proteins.
All the transfection experiments were repeated at least three times.
Immunoprecipitation and Western Blot
The cell lysates were prepared with lysis buffer (10 mM HEPES [pH 7.4],
150mMNaCl, 30 mMEDTA) containing 0.5% Triton X-100 and protease inhib-
itor cocktail (Roche). Lysis was carried out in ice-cold lysis buffer for 10 min on
ice followed by sonication. Protein A agarose beadswere used for immunopre-
cipitation as previously described (Shan et al., 2008). For western blot, protein
samples were separated on SDS-PAGE gels and then transferred to PVDF
membranes (Millipore). Membranes were processed following the HyGLO
Quick Spray western blotting protocol (Denville).
MicroRNA Profiling
Profiling of mature miRNA expression was performed with Applied Biosys-
tems’ TaqMan microRNA assays with 48-plex reverse transcription and indi-
vidual TaqMan microRNA real-time PCR assays according to protocols
provided by the vendor as described previously (Szulwach et al., 2010). Rela-
tive quantities of miRNA were determined via the DDCt method (Livak and
Schmittgen, 2001). All relative quantity calculations were calibrated to control
samples. Three biological replicates were assayed.
Statistical Methods
We used single factor analysis of variance to show significant differences
between control and metal chelator treatment. We performed post-hoc t testsC(two samples assuming equal variances) to determine significance and indi-
cated the p value. For all the presented data except noted otherwise, we
repeated at least three times, and triplicate samples were analyzed each
time. A representative experiment with triplicate samples is shown. Values
shown are mean ± SD for triplicate samples.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at
doi:10.1016/j.cmet.2012.04.021.
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